April 26th 2024
During a Case-Based Roundtable® event, Stanley M. Marks, MD, moderated a discussion on the impact of cardiac adverse events on patients who receive a Bruton tyrosine kinase inhibitor for chronic lymphocytic leukemia.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Benefit From MURANO Trial in CLL Sustained With Subsequent Therapy
December 9th 2020An analysis from the MURANO trial showed that venetoclax in combination with rituximab led to a more than doubling of time to next treatment compared with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.
Read More
Acalabrutinib Demonstrates Low Cardiac Risk in Chronic Lymphocytic Leukemia
December 8th 2020In a pooled analysis of 4 clinical trials in chronic lymphocytic leukemia, patients who received treated with acalabrutinib monotherapy had a low incidence of cardiac toxicities leading to treatment discontinuation, according to a presentation given during the American Society of Hematology Annual Meeting.
Read More
Significant Responses Seen With Investigational BTK Inhibitor in Pretreated CLL/SLL Population
December 8th 2020A high objective response rate was observed in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma treated with LOXO-305, according to results of the phase 1/2 BRUIN trial presented during the 2020 ASH Annual Meeting.
Read More
Liso-Cel Achieves High MRD Negativity Rate in High-Risk CLL/SLL
December 8th 2020Chimeric antigen receptor T-cell therapy with lisocabtagene maraleucel led to rapid and durable responses in patients with high-risk relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Read More
Ublituximab Doublet Bests Chemoimmunotherapy in Chronic Lymphocytic Leukemia
December 7th 2020In the phase 3 UNITY-CLL study, ublituximab in combination with umbralisib demonstrated synergistic activity in patients with chronic lymphocytic leukemia compared with standard of care chemoimmunotherapy irrespective of prior treatment.
Read More
Pooled Analysis Supports Use of Acalabrutinib in Patients With Chronic Lymphocytic Leukemia
December 7th 2020Jennifer R. Brown, MD, PhD, discusses the implications of the findings from a pooled analysis of cardiovascular events from studies of the next-generation BTK inhibitor acalabrutinib monotherapy as treatment of patients with chronic lymphocytic leukemia.
Watch
Venetoclax/Rituximab Shows 5-Year Survival Benefit in Relapsed/Refractory CLL
December 5th 2020Sustained progression-free survival and overall survival benefit at 5 years were observed in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia treated with the combination of venetoclax plus rituximab compared with bendamustine plus rituximab in the MURANO trial.
Read More
Placebo following a fixed-treatment duration of ibrutinib combined with venetoclax achieved similar 1-year disease-free survival results compared with patients who remained on ibrutinib following confirmed undetectable minimal residual disease in patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.
Read More
Rolling Submission of BLA to FDA Initiated for Ublituximab Plus Umbralisib in CLL
December 1st 2020A rolling submission of a Biologics License Application to the FDA has been initiated for the combination of ublituximab plus umbralisib as treatment of patients with chronic lymphocytic leukemia .
Read More
Expert Reviews Sequencing Strategies for Explosion of New CLL Treatment Options
November 4th 2020While the treatment landscape for chronic lymphocytic leukemia has expanded with an explosion of new therapeutic options, physicians are plagued with questions about sequencing therapies for those who progress following therapy in the first-line setting, and little data exists to guide optimal therapy selection, according to Anthony Mato, MD.
Read More
Brander Details Different Therapies and Modalities for Treatment of CLL in the Second Line
October 29th 2020During a Targeted Oncology Case Based Peer Perspectives event, Danielle Brander, MD, assistant professor of Medicine at Duke Cancer Institute in Durham, NC, discussed options for treating a 53-year-old female patients with chronic lymphocytic leukemia.
Read More
The Battle for the Front Line in CLL Moves Away From Chemoimmunotherapy
October 14th 2020Traditional frontline chemoimmunotherapy regimens used to be the gold standard for treating patients with newly diagnosed chronic lymphocytic leukemia. However, over time, targeted therapies have been inching out the use of chemoimmunotherapy to become the preferred approach in this setting.
Read More
Acalabrutinib Demonstrates Superior PFS Over Standard-0f-Care in Relapsed/Refractory CLL
September 12th 2020Acalabrutinib sustained superiority in terms of extended progression-free survival with a tolerable safety profile in patients with relapsed/refractory chronic lymphocytic leukemia, which was inclusive of patients with high-risk features, results from the phase 3 ASCEND trial (NCT02970318) show.
Read More